Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis. - Related Studies

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis.

This study is currently recruiting participants.

Study NCT00033371. Last updated on August 20, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Colorectal Cancer
		Precancerous/Nonmalignant Condition

2	Additional conditions recognized in this trial
		Adenomatous Polyposis Coli
		Colorectal Neoplasms
		Precancerous Conditions

3	More general conditions related to this trial
		Adenoma
		Adenomatous Polyps
		Colonic Diseases
		Colonic Neoplasms
		Digestive System Diseases
		Digestive System Neoplasms
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Genetic Diseases, Inborn
		Intestinal Diseases
		Intestinal Neoplasms
		Intestinal Polyposis
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Neoplastic Syndromes, Hereditary
		Rectal Diseases

4	Interventions listed in this trial
		celecoxib
		eflornithine
		placebo

5	More general drug interventions related to this trial
		Analgesics
		Analgesics, Non-Narcotic
		Anti-Infective Agents
		Anti-Inflammatory Agents
		Anti-Inflammatory Agents, Non-Steroidal
		Antineoplastic Agents
		Antiparasitic Agents
		Antiprotozoal Agents
		Antirheumatic Agents
		Central Nervous System Agents
		Cyclooxygenase Inhibitors
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Sensory System Agents
		Therapeutic Uses
		Trypanocidal Agents

6	Sponsors listed in this trial
		M.D. Anderson Cancer Center
		National Cancer Institute (NCI)